We are live on ! Find out more
BLRX

BioLineRX
BLRX

22 hedge funds and large institutions have $7.3M invested in BioLineRX in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

15% less funds holding

Funds holding: 26 → 22 (-4)

18% less capital invested

Capital invested by funds: $8.87M → $7.3M (-$1.57M)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
22
Holders Change
-4
Holders Change %
-15.38%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
+$335K
2
Morgan Stanley
Morgan Stanley
New York
+$67.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$33.5K
4
Jane Street
Jane Street
New York
+$16.8K
5
UBS Group
UBS Group
Switzerland
+$7.46K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$134K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$56K
3
LTFS
Ladenburg Thalmann Financial Services
Florida
-$36.7K
4
Wolverine Trading
Wolverine Trading
Illinois
-$13K
5
WSCM
Wellington Shields Capital Management
New York
-$11K

BLRX Hedge Fund Activity: Q4 2016 in Review

22 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2016, worth a combined $7.3M — down 18% from $8.87M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BLRX and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 8 added.

The largest buyer was Senvest Management, adding an estimated $335K. The largest seller was Virtu KCG Holdings, cutting an estimated $134K.

  • 22 institutional investors held BioLineRX (BLRX) as of Q4 2016, down from 26 in Q3 2016.
  • Funds reported $7.3M of BioLineRX stock for Q4 2016, down 18% quarter-over-quarter.
  • 1 fund opened new BioLineRX positions in Q4 2016 and 5 closed out, a net change of -4 holders.
  • The largest BioLineRX buyer in Q4 2016 was Senvest Management, an estimated $335K added.
  • The largest BioLineRX seller in Q4 2016 was Virtu KCG Holdings, an estimated $134K sold.

Based on aggregated 13F filings for Q4 2016.